Skip to main content
Premium Trial:

Request an Annual Quote

Diagnovus, Cincinnati Children's Hospital Ink Option Agreement for EoE Assay

Premium

Molecular diagnostics company Diagnovus has entered an agreement to validate a molecular test for eosinophilic esophagitis (EoE) and potentially license the test from developer Cincinnati Children's Hospital Medical Center.

EoE, also called inflammatory esophagitis, is diagnosed by the presence of white blood cell-containing infiltrate and a corrugated appearance in the esophagus. The disorder occurs in both adults and children, and is thought to be caused primarily by food allergies.

Correct diagnosis is especially important to guiding treatment in children, who may languish with symptoms that resemble gastroesophageal reflux but do not respond to typical anti-reflux medications.

The EoE assay was developed from a set of esophageal biopsy samples from children diagnosed with EoE and some children without the condition, yielding a 96-gene array measuring expression levels of many inflammation-related genes. The assay used low-density TaqMan qPCR arrays from Life Technologies.

A study validating the array was recently published in the journal Gastroenterology. In that paper, the assay was vetted against a collection of 194 samples of mixed diagnosis, including patients in remission from EoE. The assay identified adult and pediatric EoE patients with 96 percent sensitivity and 98 percent specificity, and could discriminate patients in remission from those with normal esophagi. The test could also be run using FFPE-derived RNA, the authors noted.

An accompanying editorial noted that the paper's findings "provide proof of principle for the use of a tissue-based molecular test in the diagnosis of EoE and highlight the advantages of such techniques over histologic analysis."

Cincinnati Children's has filed for several patents on the technology, one of which has been issued. Diagnovus, based in Nashville, Tenn., has entered into an option agreement with Cincinnati Children's for the assay.

Diagnovus recently announced the launch of an eight-gene, real-time PCR array test for Barrett's Esophagus, expanding on its growing line of personalized diagnostics for rare and orphan diseases.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.